Complement Therapeutics targeting geographic atrophy
Geographic atrophy causes retinal degeneration and incurable visual impairment in the elderly. Based on genome-wide association studies and protein stainings in the patient eye, the complement system was described a contributor to disease progression.
Today I updated my knowledge regarding complement targeting therapies for AMD in clinical trials. I share with you my personal notes. I categorized 1st and 2nd generation therapeutics based on the strategy and target protein.
For further readings follow the pubmed IDs (PMID) or the identification code given of ClinicalTrials.gov (NCT).